 | |
 | |
| Clinical data | |
|---|---|
| Other names | trimeprazine, trimeprazine (BANUK), trimeprazine (USANUS) |
| AHFS/Drugs.com | International Drug Names |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Anti-allergic agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Liver |
| Eliminationhalf-life | 4.78 ± 0.59 hours[3] |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.001.434 |
| Chemical and physical data | |
| Formula | C18H22N2S |
| Molar mass | 298.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Alimemazine (INN), also known astrimeprazine, commonly provided as atartrate salt, is aphenothiazine derivative that is used as anantipruritic (it prevents itching from causes such aseczema orpoison ivy, by acting as anantihistamine).[4] It also acts as asedative,hypnotic, andantiemetic for prevention ofmotion sickness.
Despite being structurally related to the moleculechlorpromazine, it is not used as anantipsychotic.[5]
Brand names include Nedeltran, Panectyl, Repeltin, Teraligen, Therafene, Theraligene, Theralen, Thegalin, Theralene, Vallergan, Vanectyl, and Temaril.
In the Russian Federation, it is sold under the brand name Teraligen for the treatment of anxiety disorders (includingGAD), organic mood disorders, sleep disturbances, personality disorders accompanied by asthenia and depression,somatoformautonomic dysfunction and variousneuroses.[6]
In the United States, theFood and Drug Administration (FDA) has notapproved it for human use, and it can only be prescribed by veterinarians.
A novelcombination drug that combines alimemazine withprednisolone and sold under thebrand nameTemaril-P is licensed as an antipruritic andantitussive in dogs (called Vanectyl P in Canada).[7] Ageneric version of the combinationtrimeprazine/prednisolone was approved by the USFood and Drug Administration (FDA) in June 2024.[8][9]
